Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas - PubMed (original) (raw)

. 2012 Jan 29;44(3):251-3.

doi: 10.1038/ng.1102.

Alberto Broniscer, Troy A McEachron, Charles Lu, Barbara S Paugh, Jared Becksfort, Chunxu Qu, Li Ding, Robert Huether, Matthew Parker, Junyuan Zhang, Amar Gajjar, Michael A Dyer, Charles G Mullighan, Richard J Gilbertson, Elaine R Mardis, Richard K Wilson, James R Downing, David W Ellison, Jinghui Zhang, Suzanne J Baker; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project

Affiliations

• PMID: 22286216
• PMCID: PMC3288377
• DOI: 10.1038/ng.1102

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

Gang Wu et al. Nat Genet. 2012.

Abstract

To identify somatic mutations in pediatric diffuse intrinsic pontine glioma (DIPG), we performed whole-genome sequencing of DNA from seven DIPGs and matched germline tissue and targeted sequencing of an additional 43 DIPGs and 36 non-brainstem pediatric glioblastomas (non-BS-PGs). We found that 78% of DIPGs and 22% of non-BS-PGs contained a mutation in H3F3A, encoding histone H3.3, or in the related HIST1H3B, encoding histone H3.1, that caused a p.Lys27Met amino acid substitution in each protein. An additional 14% of non-BS-PGs had somatic mutations in H3F3A causing a p.Gly34Arg alteration.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing financial interests.

Figures

Figure 1. Recurrent somatic mutations in H3F3A and HIST1H3B

Sanger sequencing chromatograms showing representative H3F3A or HIST1H3B mutations encoding p.K27M substitutions, or H3F3A mutation encoding p.G34R substitution in the indicated tumour compared to matched normal DNA. Arrow indicates mutation. SJHGG001 and SJHGG079 are DIPGs, SJHGG043 is a non-brainstem paediatric glioblastoma.

Comment in

• Cancer genomics: Histone modification at the gene level.
  Burgess DJ. Burgess DJ. Nat Rev Genet. 2012 Feb 14;13(3):148-9. doi: 10.1038/nrg3181. Nat Rev Genet. 2012. PMID: 22330763 No abstract available.
• Histone modification at the gene level.
  Burgess DJ. Burgess DJ. Nat Rev Cancer. 2012 Feb 24;12(3):156. doi: 10.1038/nrc3233. Nat Rev Cancer. 2012. PMID: 22362212 No abstract available.

Similar articles

• K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
  Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C. Khuong-Quang DA, et al. Acta Neuropathol. 2012 Sep;124(3):439-47. doi: 10.1007/s00401-012-0998-0. Epub 2012 Jun 3. Acta Neuropathol. 2012. PMID: 22661320 Free PMC article.
• Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
  Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA. Castel D, et al. Acta Neuropathol. 2015 Dec;130(6):815-27. doi: 10.1007/s00401-015-1478-0. Epub 2015 Sep 23. Acta Neuropathol. 2015. PMID: 26399631 Free PMC article.
• Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
  Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C. Gits HC, et al. Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9. Acta Neuropathol Commun. 2018. PMID: 30049282 Free PMC article.
• Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
  Mendez FM, Núñez FJ, Garcia-Fabiani MB, Haase S, Carney S, Gauss JC, Becher OJ, Lowenstein PR, Castro MG. Mendez FM, et al. Neuro Oncol. 2020 Feb 20;22(2):195-206. doi: 10.1093/neuonc/noz218. Neuro Oncol. 2020. PMID: 32078691 Free PMC article. Review.
• Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.
  Panditharatna E, Yaeger K, Kilburn LB, Packer RJ, Nazarian J. Panditharatna E, et al. Cancer Genet. 2015 Jul-Aug;208(7-8):367-73. doi: 10.1016/j.cancergen.2015.04.008. Epub 2015 May 1. Cancer Genet. 2015. PMID: 26206682 Review.

Cited by

• Emerging roles of cancer-associated histone mutations in genomic instabilities.
  Yadav P, Jain R, Yadav RK. Yadav P, et al. Front Cell Dev Biol. 2024 Oct 8;12:1455572. doi: 10.3389/fcell.2024.1455572. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39439908 Free PMC article. Review.
• In vitro Modeling of Embryonal Tumors.
  Custers L, Paassen I, Drost J. Custers L, et al. Front Cell Dev Biol. 2021 Feb 26;9:640633. doi: 10.3389/fcell.2021.640633. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33718380 Free PMC article. Review.
• WEE1 tyrosine kinase, a novel epigenetic modifier.
  Mahajan K, Mahajan NP. Mahajan K, et al. Trends Genet. 2013 Jul;29(7):394-402. doi: 10.1016/j.tig.2013.02.003. Epub 2013 Mar 26. Trends Genet. 2013. PMID: 23537585 Free PMC article. Review.
• The molecular hallmarks of epigenetic control.
  Allis CD, Jenuwein T. Allis CD, et al. Nat Rev Genet. 2016 Aug;17(8):487-500. doi: 10.1038/nrg.2016.59. Epub 2016 Jun 27. Nat Rev Genet. 2016. PMID: 27346641 Review.
• The role of chromatin remodeling in medulloblastoma.
  Jones DT, Northcott PA, Kool M, Pfister SM. Jones DT, et al. Brain Pathol. 2013 Mar;23(2):193-9. doi: 10.1111/bpa.12019. Brain Pathol. 2013. PMID: 23432644 Free PMC article. Review.

References

1. 1. Broniscer A, Gajjar A. The oncologist. 2004;9:197–206. - PubMed
2. 1. Paugh BS, et al. Journal of clinical oncology. 2011;29:3999–4006. - PMC - PubMed
3. 1. Paugh BS, et al. Journal of clinical oncology. 2010;28:3061–8. - PMC - PubMed
4. 1. Barrow J, et al. Neuro-oncology. 2011;13:212–22. - PMC - PubMed
5. 1. Bax DA, et al. Clinical cancer research. 2010;16:3368–77. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • GlyGen glycoinformatics resource
  • The Weizmann Institute of Science GeneCards and MalaCards databases